Study of PYX-201 with Pembrolizumab for Advanced Solid Tumors
This study is testing a new combination of two drugs, PYX-201 and pembrolizumab, for people with advanced solid tumors. The main goal is to find the best and safest doses of PYX-201 when given with pembrolizumab. Researchers will also look at any side effects you might experience over about two years. You could be eligible if you are 18 or older and have certain advanced solid tumors, including specific types of breast cancer, head and neck cancer, gastric cancer, or cervical cancer. The study is currently recruiting 220 participants.
- Study design
- This is an interventional study involving 220 participants. It aims to determine the recommended doses and maximum tolerated dose of the drug combination.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for adverse events and changes in laboratory results for up to approximately 2 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
At a glance
Conditions
Where it's being run
19 sites across 9 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants who Experience a Dose-Limiting Toxicity (DLT)Day 1 to Day 21
- Number of Participants who Experience an Adverse Event (AE)Up to approximately 2 years
- Number of Participants who Experience Clinically Significant Changes in Clinical Laboratory ParametersUp to approximately 2 years
- Number of Participants who Experience Clinically Significant Changes in Vital SignsUp to approximately 2 years
- Number of Participants who Experience Clinically Significant Changes in electrocardiogram (ECG) ParametersUp to approximately 2 years